The Clinical Study of SHR-7631 for Injection in Patients With Advanced Solid Tumors
This study is an open-label, phase I clinical trial of SHR-7631 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.
Advanced Solid Tumors
DRUG: SHR-7631
Maximum tolerated dose (MTD) or maximum administered dose (MAD), 12 months|Incidence and severity of adverse events (AEs)/serious adverse events (SAEs) (CTCAE v5.0), 36 months
PK parameter: Tmax, 36 months|PK parameter: Cmax, 36 months|PK parameter: AUC0-t, 36 months|PK parameter: AUC0-âˆž, 36 months|PK parameter: t1/2, 36 months|PK parameter: MRT (mean residence time), 36 months
This study is an open-label, phase I clinical trial of SHR-7631 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.